Ruxolitinib

Biochem/physiol Actions Reparixin is a noncompetitive allosteric inhibitor of the inflammatory CXCL8 (IL-8) chemokine receptors CXCR1 and CXCR2 with IC50 values of 1 nM for CXCR1 and 100 nM for CXCR2. It is believed to prevent receptor signaling

General description The gene encoding retinoblastoma-associated protein (RB1) is a tumor suppressor gene localized on human chromosome 13q14.2.

Rho Kinase Inhibitor III, Rockout is a cell permeable ATP-competitive Rock (Rho Kinase) inhibitor discovered by an image based, high throughput screen of a wound healing cell monolayer. When discovered Rock (Rho Kinase) Inhibitor III, Rockout was

The RPI riboflavin (vitamin B2) is mainly used in research facilities and chemical laboratories to conduct wide range of experiments. It is available in sturdy bottle that endures heavy and rigorous usage.

Research area: Apoptosis N-terminal His6-tagged, recombinant, human ROCK-I amino acids 17-535 autoactivated by incubating with Mg/ATP and redialysed to remove excess ATP Product Source: expressed by baculovirus in Sf21 insect cells Application

Research area: Apoptosis N-terminal His6-tagged, recombinant, human ROCK-I amino acids 17-535 autoactivated by incubating with Mg/ATP and redialysed to remove excess ATP Product Source: expressed by baculovirus in Sf21 insect cells Application

RPI-1 is a cell-permeable, indolinone-based ATP-competitive tyrosine kinase inhibitor that is known to target Ret, EGFR, and Met. Increased tumorigenicity, motility, and invasiveness have been described as biological consequences of HGF/Met

RPI-1 is a cell-permeable, indolinone-based ATP-competitive tyrosine kinase inhibitor that is known to target Ret, EGFR, and Met. Increased tumorigenicity, motility, and invasiveness have been described as biological consequences of HGF/Met

RPI-1 is a cell-permeable, indolinone-based ATP-competitive tyrosine kinase inhibitor that is known to target Ret, EGFR, and Met. Increased tumorigenicity, motility, and invasiveness have been described as biological consequences of HGF/Met

RPI-1 is a cell-permeable, indolinone-based ATP-competitive tyrosine kinase inhibitor that is known to target Ret, EGFR, and Met. Increased tumorigenicity, motility, and invasiveness have been described as biological consequences of HGF/Met

RPI-1 is a cell-permeable, indolinone-based ATP-competitive tyrosine kinase inhibitor that is known to target Ret, EGFR, and Met. Increased tumorigenicity, motility, and invasiveness have been described as biological consequences of HGF/Met

RU-302 is a pan TAM inhibitor that blocks the interface between the TAM Ig1 ectodomain and the Gas6 Lg domain. RU-302 effectively blocks Gas6-inducible Axl receptor activation with a low micromolar IC 50 in cell assays, and suppresses lung cancer